Psychiatric drug development has a sobering statistic: nearly 96% of neuropsychiatric drugs fail, including many aimed at autism, bipolar disorder, and schizophrenia. Despite decades of research, traditional animal models and early-stage drug discovery methods have struggled to translate into effective treatments for complex brain conditions. For families navigating autism and other neurodivergent diagnoses, that failure […]
